Microcurrent Stimulation 100ile Rent-To-Purchase Option - cost is $75 per month. First payment is $200 which includes $125 security, $75 for the first month security plus $10 shipping. Then the charge is $75 per month for the next 8 months until the unit is fully paid off. Total cost of the unit is $875.
100% of the rental and security is applied against the purchase price. User has the option to return the unit, and the user would only be charged $75 per month for the months used, and the security would be returned.
MicroCurrent Stimulation (MCS) is an enhanced adaptation of a FDA approved therapy used by anesthesiologists, orthopedic surgeons, plastic surgeons and rehabilitative specialists to promote the healing of wounds and transplanted tissues as well as to treat pain. User Experiences
Not only is this the only unit based on all 5 research studies done to date, but it has a unique Regulator and Processor that uniquely adjusts the microcurrent based on each individual's retinal tissue acceptance of the microcurrent (1,000 times per minute). The higher frequencies in the beginning of each 5-minute session helps relax the retinal tissue, then the lower frequencies stimulate the retina and ATP (energy) production within the retinal cells. The treatments also attracts adult stem cells to help stimulate possible cell regeneration.
The theory is that MCS helps
Although the exact mechanism of action of MCS has not yet been established scientifically, research suggests that microcurrent electrical stimulation device approximates the level of electrical activity present in a healthy eye, resulting in stimulating retinal activity and energizing dormant cells, as well as improving microvascular circulation, nerve conduction and velocity.
Microcurrent stimulation increases ATP (energy) synthesis in the retinal cells needed for membrane viability and waste management (a major concern for those with dry macular degeneration as excess waste not reabsorbed and eliminated results in waste accumulation called "drusen").
The treatment of patients with Macular Degeneration and Retinitis Pigmentosa entails the periodic administration of very precise amounts of tightly controlled electrical current through electrodes applied to the skin at specific areas around the eye. The electrical current is used to stimulate the retina as well as the diseased macula in order to help protect sight. The procedure is safe, noninvasive and painless and no side effects or adverse reactions have been observed.
This is the home unit version of the Microcurrent Stimulation (MCS 400 ile). The frequency settings were used in the studies described below. It is preset automatically to run through 4 frequencies in a preset 5-minute cycle before turning off. The four frequencies are: 292Hz for 30 seconds, 30Hz for 30 seconds, 9.1Hz for 2 minutes, then finally .3Hz for 2 minutes. Voltage is up to 22 and amps range 700 microAmps.
There are other microcurrent stimulation units available, but they have to be specifically calibrated both in frequency and timing to ensure proper gentle wave currents for your eyes. Most of these units are actually TENS units designed more for wound healing and bone repair.
No side effects or adverse outcomes related to this treatment have been seen so far. No increase in the conversion to the wet form of ARMD has been seen to those who have been treated.
In a consensus statement by the NIH reports that, "One of the advantages...is that the incidence of adverse affects is substantially lower than that of many drugs or other accepted medical procedures used for the same conditions."
The 1st three studies were summarized from the October, 2002 issue of the Townsend Newsletter:
The first study on MCS was a 2-year study done from 1983-1985 on 114 patients by Grace Halloran, Ph.D. The results of the study were as follows:
A ten-year clinical study was done by Drs. Jarding and Michael on the use of MCS to treat Macular Degeneration. Of the 400 eyes studied, the results were as follows:
Damon Miller, MD, reviewed the results of using Microcurrent Stimulation in the treatment of Stargardt's Disease, Retinitis Pigmentosa and other degenerative retinal diseases. His results indicate the following:
There are several metabolic processes that are enhanced through the use of Microcurrent Stimulation. The first to boost the cells' ability to rid themselves of waste products. A cell with "stuck" waste products becomes a dead cell and interferes with cellular communication throughout the area where it is located. Cells need to take in nutrients and eliminate waste like all other living organisms. The energy supplied by Microcurrent Stimulation innervates cells to become vital and less sluggish.
The second way Microcurrent Stimulation works is by increasing blood supply to the area stimulated. By increasing blood flow to the area cells and tissues are nourished, refreshed and oxygenation is increased.
In general, the electrical current gently wakes up the cells from sleep and stimulates the healing process.
As its premier research project newly announced, the Macular Degeneration Foundation plans to conduct a nationwide controlled clinical trial to define the vision-enhancing value of administering what it terms Microcurrent Stimulation (MCS). The Foundation's two-year preliminary MCS trial involving 120 patients resulted in an average of:
Patients were able to sustain these vision improvements over time by periodic self-administration of booster treatments and many report that this therapy has made a remarkable difference to their lives.
From May 2001 to November 2002, a pilot study by Dr. Ed Paul treated subjects with retinal diseases such as AMD, Stargardt's, and retinitis pigmentosa with MCS. Overall,
MCS may be helpful for: Retinitis Pigmentosa, Stargardt's Disease, Cone-Rod Dystrophy, other types of retinal dystrophies.
MCS therapy is considered an "off label" use of an approved medical device. Off label usage of FDA approved devices and drugs are commonly practiced by doctors without interference from the FDA and allows doctors to practice in a manner they feel most beneficial to their patients.
When ordering, please let us know your specific eye diagnosis.
MCS is contraindicated for those with pacemakers, or who are pregnant. If you have a neurological disorder such as epilepsy, please discuss with your doctor first before using MCS.How it Works Studies Safety Studies Pricing Abstracts FDA Note Directions Usage
The data presented here has not been reviewed by the FDA, nor has it been peer reviewed. The microcurrent devices used are approved by the FDA for the treatment of pain, but they have not been approved for other uses. The use of a device for an off-label use by a physician is legal. The use of microcurrent stimulation discussed here is only one part of a comprehensive program for supporting visual health, and should not replace any treatment prescribed by your physician.
There is a full 1 year replacement warranty on any defective unit (based on normal wear and tear).
"My name is Max Mandolini, and I am a Vision Educator in Long Beach, California. My father Leandro, who lives in Italy, was diagnosed with a form of Wet AMD in his left eye. He is 83, in good overall health: his major problem was an operation for a heart condition in 1998. After that, he has been taking some blood thinning drugs, that may have contributed to leakage in the macular area.
"Late in June 2006, he received an endovitreous injection of Avastin (a steroid-type drug). At that time his vision in OS was 1/10 (Italian measurement). Late in July, I visited him and he started taking some supplements (EPA DHA, Lutein, and an eye formula). Also, he started a daily treatment of MCS ile 1000), which I had purchased from NaturalEyeCare.
"In September, Leandro started complaining of deterioration of vision in his other eye (OD), and was given an injection of Avastin. At that point, he almost could not read and write, and even insecure when walking outside.
"He continued his regime of daily supplementation and MCS treatment. Early in November, he told that he was noticing an improvement in his vision. His latest medical exam (Nov 30) confirmed the improvement to an unpredictable extent: his vision had improved from 20/200 to 20/40.
"The doctor, dumbfounded, has scheduled an appointment for an OCT scan in January. My father, overjoyed, continues his regime."
-- Max Mandolini, NEI Educator - 1/7/07More comments